Iovance Biotherapeutics, Inc. develops and delivers tumor infiltrating lymphocyte (TIL) therapies for cancer treatment. The company focuses on harnessing the human immune system to target and destroy cancer cells, with a commitment to innovation in cell therapy, including gene-edited therapies. Iovance operates primarily in the biotechnology sector, serving patients with various solid tumors, and has facilities in San Carlos, California; Tampa, Florida; and Philadelphia, Pennsylvania.
